{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:53:57Z","timestamp":1793915637875,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07925-5","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:48:16Z","timestamp":1772444896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of immunosuppressants and immunomodulators in juvenile myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaoling","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YanMei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-6264","authenticated-orcid":false,"given":"Rong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"1","key":"7925_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"7925_CR2","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ncl.2016.06.017","volume":"34","author":"JM Bhatt","year":"2016","unstructured":"Bhatt JM. The Epidemiology of Neuromuscular Diseases. Neurol Clin. 2016;34(4):999\u20131021.","journal-title":"Neurol Clin"},{"key":"7925_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48\u201349","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014;48\u201349:143\u20138.","journal-title":"J Autoimmun"},{"issue":"1","key":"7925_CR4","first-page":"47","volume":"151","author":"P Tolosa-Tort","year":"2015","unstructured":"Tolosa-Tort P, Chiquete E, Dom\u00ednguez-Moreno R, Vega-Boada F, Reyes-Melo I, Flores-Silva F, et al. Myasthenia gravis in adults of institutions pertaining to the Mexican public health system: an analysis of hospital discharges during 2010. Gac Med Mex. 2015;151(1):47\u201353.","journal-title":"Gac Med Mex"},{"key":"7925_CR5","doi-asserted-by":"publisher","first-page":"1119294","DOI":"10.3389\/fneur.2023.1119294","volume":"14","author":"Y Lin","year":"2023","unstructured":"Lin Y, Kuang Q, Li H, Liang B, Lu J, Jiang Q, et al. Outcome and clinical features in juvenile myasthenia gravis: A systematic review and meta-analysis. Front Neurol. 2023;14:1119294.","journal-title":"Front Neurol"},{"key":"7925_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3389\/fneur.2020.00743","volume":"11","author":"K O\u2019Connell","year":"2020","unstructured":"O\u2019Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020;11:743.","journal-title":"Front Neurol"},{"key":"7925_CR7","doi-asserted-by":"crossref","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6).","DOI":"10.3390\/jcm11061597"},{"key":"7925_CR8","doi-asserted-by":"crossref","unstructured":"Munot P, Robb SA, Niks EH, Palace J. 242nd ENMC International workshop: diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1\u20133 March 2019. Neuromuscul Disord. 2020;30(3):254\u2013264.","DOI":"10.1016\/j.nmd.2020.02.001"},{"issue":"6","key":"7925_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/MOP.0b013e328365ad16","volume":"25","author":"WK Liew","year":"2013","unstructured":"Liew WK, Kang PB. Update on juvenile myasthenia gravis. Curr Opin Pediatr. 2013;25(6):694\u2013700.","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"7925_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113\u201324.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"7925_CR11","first-page":"Cd002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12(12):Cd002277.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"7925_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, Qi W, Hao L, Guo X. The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis. CNS Drugs. 2024;38(2):93\u2013104.","journal-title":"CNS Drugs"},{"issue":"5","key":"7925_CR13","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00415-024-12247-x","volume":"271","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T, Tan X, Wang S, Qu R, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298\u2013308.","journal-title":"J Neurol"},{"issue":"1","key":"7925_CR14","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1186\/s12967-024-05751-1","volume":"22","author":"J Gu","year":"2024","unstructured":"Gu J, Qiao Y, Huang R, Cong S. Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis. J Transl Med. 2024;22(1):955.","journal-title":"J Transl Med"},{"key":"7925_CR15","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"7925_CR16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"10","key":"7925_CR17","first-page":"1034","volume":"25","author":"RY Wang","year":"2023","unstructured":"Wang RY, Chen H, Huang ZX, Chen Y, Zhong JM. Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis. Zhongguo Dang Dai Er Ke Za Zhi. 2023;25(10):1034\u20139.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"9","key":"7925_CR18","first-page":"964","volume":"22","author":"JW Li","year":"2020","unstructured":"Li JW, Fang F, Ren XT, Zhang WH, Yang XY, Ren CH, et al. Clinical effect of tacrolimus in the treatment of myasthenia gravis in children. Zhongguo Dang Dai Er Ke Za Zhi. 2020;22(9):964\u20139.","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"7925_CR19","first-page":"124","volume":"53","author":"R Matsuura","year":"2021","unstructured":"Matsuura R, Hamano S, Oba A, Nonoyama H, Daida A, Kubota J, et al. Efficacy of tacrolimus therapy for patients with childhood-onset myasthenia gravis. NO HATTATSU. 2021;53:124\u20138.","journal-title":"NO HATTATSU"},{"key":"7925_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jocn.2023.08.022","volume":"116","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang M, Zhang L, Zhou S, Li W. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis. J Clin Neurosci. 2023;116:93\u20138.","journal-title":"J Clin Neurosci"},{"key":"7925_CR21","doi-asserted-by":"crossref","unstructured":"Bi Z, Cao Y, Lin J, Zhang Q, Liu C, Gui M, et al. Long-term improvement in a chinese cohort of glucocorticoid-resistant childhood-onset myasthenia gravis patients treated with tacrolimus. Front Neurol. 2022;13.","DOI":"10.3389\/fneur.2022.820205"},{"key":"7925_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jns.2018.10.027","volume":"396","author":"T Omata","year":"2019","unstructured":"Omata T, Fukui K, Kodama K, Watanabe Y, Aoyama H, Fujii K, et al. Ocular myasthenia gravis patients following the administration of tacrolimus and steroids. J Neurol Sci. 2019;396:30\u20132.","journal-title":"J Neurol Sci"},{"key":"7925_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2017.08.014","volume":"77","author":"C Liu","year":"2017","unstructured":"Liu C, Gui M, Cao Y, Lin J, Li Y, Ji S, et al. Tacrolimus Improves Symptoms of Children with Myasthenia Gravis Refractory to Prednisone. Pediatr Neurol. 2017;77:42\u20137.","journal-title":"Pediatr Neurol"},{"key":"7925_CR24","doi-asserted-by":"crossref","unstructured":"Wang G, Kessi M, Huang X, Zhang W, Zhang C, He F, et al. Treatment of juvenile myasthenia gravis with tacrolimus: a cohort study. Eur J Neurol. 2024;31(12).","DOI":"10.1111\/ene.16466"},{"issue":"3","key":"7925_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/cen3.12585","volume":"11","author":"M Hayashi","year":"2020","unstructured":"Hayashi M, Nomura Y. Aims of the Childhood Myasthenia Gravis Study Group in Japan. Clin Experimental Neuroimmunol. 2020;11(3):185\u201391.","journal-title":"Clin Experimental Neuroimmunol"},{"issue":"11","key":"7925_CR26","first-page":"1275","volume":"42","author":"C Liu","year":"2017","unstructured":"Liu C, Wang X, Xie L, Peng J, Wu L, Zheng X. Analysis for the effect of different regimens on ocular myasthenia gravis in children. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017;42(11):1275\u20139.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"5\u20136","key":"7925_CR27","first-page":"201","volume":"31","author":"Y Nomura","year":"2009","unstructured":"Nomura Y, Hachimori K, Nagao Y, Segawa M, Kimura K, Segawa M. Childhood Myasthenia Gravis in Japan\u2014Clinical Analysis of 184 Cases at Segawa Neurological Clinic for Children for 30 Years. Neuro-Ophthalmology. 2009;31(5\u20136):201\u20135.","journal-title":"Neuro-Ophthalmology"},{"issue":"Suppl 3","key":"7925_CR28","first-page":"S152","volume":"94","author":"S Sri-udomkajorn","year":"2011","unstructured":"Sri-udomkajorn S, Panichai P, Liumsuwan S. Childhood myasthenia gravis: clinical features and outcomes. J Med Assoc Thai. 2011;94(Suppl 3):S152\u2013157.","journal-title":"J Med Assoc Thai"},{"issue":"5","key":"7925_CR29","first-page":"371","volume":"49","author":"NN Qin","year":"2011","unstructured":"Qin NN, Chen RL, Ma S, Zhang XJ, Sun HL, Jing Y. Childhood-onset myasthenia gravis: the analysis of influencing factors of therapeutic effect and prognosis. Zhonghua Er Ke Za Zhi. 2011;49(5):371\u20135.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"3\u2013b","key":"7925_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1590\/S0004-282X2001000500005","volume":"59","author":"MP Morita","year":"2001","unstructured":"Morita MP, Gabbai AA, Oliveira AS, Penn AS. Myasthenia gravis in children: analysis of 18 patients. Arq Neuropsiquiatr. 2001;59(3\u2013b):681\u20135.","journal-title":"Arq Neuropsiquiatr"},{"key":"7925_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2024.04.020","volume":"156","author":"JF Brandsema","year":"2024","unstructured":"Brandsema JF, Ginsberg M, Hoshino H, Mimaki M, Nagata S, Rao VK, et al. Eculizumab in Adolescent Patients with Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study. Pediatr Neurol. 2024;156:198\u2013207.","journal-title":"Pediatr Neurol"},{"issue":"9","key":"7925_CR32","first-page":"689","volume":"55","author":"Z Fu","year":"2017","unstructured":"Fu Z, Bao XH, Wu Y, Zhou J, Zhang YH, Zhang Y, et al. Effectiveness and safety of rituximab for children with autoimmune diseases of the nervous system. Zhonghua Er Ke Za Zhi. 2017;55(9):689\u201394.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"11","key":"7925_CR33","first-page":"1050","volume":"62","author":"YN Tong","year":"2024","unstructured":"Tong YN, Wei CJ, Yang XL, Ji TY, Zhang Y, Wu Y, et al. Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis. Zhonghua Er Ke Za Zhi. 2024;62(11):1050\u20135.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"7925_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pediatrneurol.2020.07.002","volume":"111","author":"CD Zingariello","year":"2020","unstructured":"Zingariello CD, Elder ME, Kang PB. Rituximab as Adjunct Maintenance Therapy for Refractory Juvenile Myasthenia Gravis. Pediatr Neurol. 2020;111:40\u20133.","journal-title":"Pediatr Neurol"},{"key":"7925_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejpn.2022.06.009","volume":"40","author":"S Ramdas","year":"2022","unstructured":"Ramdas S, Della Marina A, Ryan MM, McWilliam K, Klein A, Jacquier D, et al. Rituximab in juvenile myasthenia gravis-an international cohort study and literature review. Eur J Pediatr Neurol. 2022;40:5\u201310.","journal-title":"Eur J Pediatr Neurol"},{"issue":"4","key":"7925_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mus.25965","volume":"57","author":"C Barraud","year":"2018","unstructured":"Barraud C, Desguerre I, Barnerias C, Gitiaux C, Boulay C, Chabrol B. Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve. 2018;57(4):603\u20139.","journal-title":"Muscle Nerve"},{"issue":"4","key":"7925_CR37","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1542\/peds.2013-0814","volume":"132","author":"J VanderPluym","year":"2013","unstructured":"VanderPluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical Characteristics of Pediatric Myasthenia: A Surveillance Study. Pediatrics. 2013;132(4):e939\u201344.","journal-title":"Pediatrics"},{"issue":"11","key":"7925_CR38","first-page":"2404","volume":"20","author":"MG Wang","year":"2016","unstructured":"Wang MG, Huang XX, Yao D, An Q, Deng XQ. Effect of glucocorticoid combined with gamma globulin in treatment of children with myasthenia gravis and its effects on immune globulin and complement of children. Eur Rev Med Pharmacol Sci. 2016;20(11):2404\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"7925_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0887-8994(99)00112-5","volume":"22","author":"D Selcen","year":"2000","unstructured":"Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40\u20133.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"7925_CR40","first-page":"119","volume":"56","author":"H Takeuchi","year":"2024","unstructured":"Takeuchi H, Matsuura R, Kikuchi K, Takeda R, Hirata Y, Koichihara R, et al. Efficacy of intravenous immunoglobulin therapy in acute phase of myasthenia gravis in children. [Japanese]. No Hattatsu. 2024;56(2):119\u201324.","journal-title":"No Hattatsu"},{"issue":"16","key":"7925_CR41","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334.","journal-title":"Neurology"},{"issue":"5","key":"7925_CR42","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr., Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, et al. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020;77(5):582\u201392.","journal-title":"JAMA Neurol"},{"issue":"7","key":"7925_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691\u2013701.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"7925_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard Jr","year":"2013","unstructured":"Howard JF Jr., Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76\u201384.","journal-title":"Muscle Nerve"},{"issue":"12","key":"7925_CR45","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"7925_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14\u201324.","journal-title":"Muscle Nerve"},{"issue":"6","key":"7925_CR47","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40272-024-00649-3","volume":"26","author":"S Ramdas","year":"2024","unstructured":"Ramdas S, Painho T, Vanegas MI, Famili DT, Lim MJ, Jungbluth H. Targeted Treatments for Myasthenia Gravis in Children and Adolescents. Paediatr Drugs. 2024;26(6):719\u201340.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"7925_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jnnp-2021-328665","volume":"93","author":"C Nelke","year":"2022","unstructured":"Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(5):548\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7925_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pediatrneurol.2025.02.007","volume":"166","author":"A Jiang","year":"2025","unstructured":"Jiang A, Hu Q, Wang Z, Wu F. Efficacy and Safety of Tacrolimus Therapy in Patients with Juvenile Myasthenia Gravis: A Single-Arm Meta-Analysis. Pediatr Neurol. 2025;166:32\u20138.","journal-title":"Pediatr Neurol"},{"issue":"11","key":"7925_CR50","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s00415-017-8616-7","volume":"264","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang S, Xi J, Li W, Zhou L, Lu J, et al. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2017;264(11):2191\u2013200.","journal-title":"J Neurol"},{"issue":"5","key":"7925_CR51","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.braindev.2012.06.012","volume":"35","author":"T Mori","year":"2013","unstructured":"Mori T, Mori K, Suzue M, Ito H, Kagami S. Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus. Brain Dev. 2013;35(5):445\u20138.","journal-title":"Brain Dev"},{"issue":"9","key":"7925_CR52","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","volume":"12","author":"S Berrih-Aknin","year":"2013","unstructured":"Berrih-Aknin S, Ragheb S, Le Panse R, Lisak RP. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev. 2013;12(9):885\u201393.","journal-title":"Autoimmun Rev"},{"key":"7925_CR53","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1196\/annals.1254.032","volume":"998","author":"M Milani","year":"2003","unstructured":"Milani M, Ostlie N, Wang W, Conti-Fine BM. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci. 2003;998:284\u2013307.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"7925_CR54","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"4","key":"7925_CR55","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/acn3.51746","volume":"10","author":"Z Fan","year":"2023","unstructured":"Fan Z, Lei L, Su S, Zhang S, Xie N, Li L, et al. Comparison between mono-tacrolimus and mono-glucocorticoid in the treatment of myasthenia gravis. Ann Clin Transl Neurol. 2023;10(4):589\u201398.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"7925_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000236781","volume":"105","author":"RA Schwartzman","year":"1994","unstructured":"Schwartzman RA, Cidlowski JA. Glucocorticoid-induced apoptosis of lymphoid cells. Int Arch Allergy Immunol. 1994;105(4):347\u201354.","journal-title":"Int Arch Allergy Immunol"},{"issue":"20","key":"7925_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","volume":"332","author":"GP Chrousos","year":"1995","unstructured":"Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351\u201362.","journal-title":"N Engl J Med"},{"issue":"6","key":"7925_CR58","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI110408","volume":"68","author":"J Grayson","year":"1981","unstructured":"Grayson J, Dooley NJ, Koski IR, Blaese RM. Immunoglobulin production induced in vitro by glucocorticoid hormones: T cell-dependent stimulation of immunoglobulin production without B cell proliferation in cultures of human peripheral blood lymphocytes. J Clin Invest. 1981;68(6):1539\u201347.","journal-title":"J Clin Invest"},{"issue":"3723","key":"7925_CR59","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1126\/science.152.3723.782","volume":"152","author":"LD Caren","year":"1966","unstructured":"Caren LD, Rosenberg LT. Steroids and serum complement in mice: influence of hydrocortisone, diethylstilbestrol, and testosterone. Science. 1966;152(3723):782\u20133.","journal-title":"Science"},{"key":"7925_CR60","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2020.00868","volume":"11","author":"T Imai","year":"2020","unstructured":"Imai T, Suzuki S, Nagane Y, Uzawa A, Murai H, Utsugisawa K. Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. Front Neurol. 2020;11:868.","journal-title":"Front Neurol"},{"issue":"5","key":"7925_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00000441-198805000-00005","volume":"295","author":"EL Arsura","year":"1988","unstructured":"Arsura EL, Bick A, Brunner NG, Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am J Med Sci. 1988;295(5):438\u201343.","journal-title":"Am J Med Sci"},{"key":"7925_CR62","doi-asserted-by":"crossref","unstructured":"Pavlekovics M, Engh MA, Lugosi K, Szabo L, Hegyi P, Terebessy T, et al. Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control. Biomedicines. 2023;11(12).","DOI":"10.3390\/biomedicines11123180"},{"issue":"2","key":"7925_CR63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","volume":"11","author":"JD L\u00fcnemann","year":"2015","unstructured":"L\u00fcnemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80\u20139.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"7925_CR64","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102(3):177\u201393.","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07925-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07925-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:04:39Z","timestamp":1775574279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07925-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7925"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07925-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"480"}}